Panbela Therapeutics, Inc.: Nasdaq/NYSE listing notice — Nasdaq delists Panbela Therapeutics; trading suspended March 7, 2024

Panbela Therapeutics, Inc.

Nasdaq notified Panbela of delisting due to failure to meet $2.5M stockholders' equity requirement.
Trading suspended at open on March 7, 2024; stock expected to quote on OTC Pink Market under PBLA.
Company has 15 days to request review of Panel's decision by Nasdaq Listing Council.
Company plans to continue filing periodic reports with SEC despite delisting.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Panbela Therapeutics, Inc. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1), 5550(b)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: stockholders equity
Rules: 5550(b)(1), 5550(b)

Exact text from the filing

s have lapsed. In the interim, the Company expects its common stock will be eligible for quotation on the OTC Pink Market under its existing symbol, “PBLA.” The Panel reached its decision because the Company is in violation of the minimum $2.5 million stockholders equity requirement in Listing Rule 5550(b)(1) and unable to comply with any of the alternative requirements in Listing Rule 5550(b). The Company has 15 days after the date it received notice of the Panel’s decision to request that the Nasdaq Listing and Hearing Review Council review the decision, or the Council may, on its own motion

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001437749-24-006889

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.